A work on the efficacy and safety of the intermittent and repeated administration of the levosimendant drug in patients with advanced cardiac insufficiency performed in the Complex Cardiology Service University Hospital of the Canary Islands (HUC), written by the Council of Health of the Government of the Canary Islands, has been honored by the Real Academy of Medicine of Santa Cruz of Tenerife with the Annual Exmo Award. Help from Santa Tenerife’s Santa Cruz to work on Cardiology. The act of entry was recently celebrated, on this occasion of telematic form, during which he was presented with the work of the cardiologist and author of the study, Dr. Martín Jesús García González, who also joined as Academic Correspondence is.
If treated by a clinical trial multicenter in which it has evaluated the efficacy and safety of intermittent intravenous intravenous infusions over 24 hours as a therapeutic strategy to reduce the incidence of increased acute injury in patients with severe cardiac insufficiency. and which is characterized by poor quality of life and frequent hospitalizations of these patients.
Conclusions
A total of 99 patients participate in the study. A group of patients receiving, in addition to treatment, are optimized for cardiac insufficiency with current recommendations, administration of a levosimendan infusion lasting 24 hours and 30 days to remove any other disease. in levosimendan, placebo.
Die volggtrekkings van die estude reseñan que la administración de levosimedán intermitente, in patients with advanced cardiac insufficiency, produces a reduction in the incidence of hospital repressions due to cardiac insufficiency inadvertently compensated and a significant increase in
This work is funded by the Ministry of Health, the Canaria Foundation for Sanitary Investigation (Funcis) and OrionPharma Laboratory.
For the Dr. Martín García, ‘received this award with a huge personal satisfaction and an unquestionable professional honor. I am very pleased with the Real Academia de Santa Cruz Medicine of Tenerife for this recognition that I have for the patients who participate in the study ”.